Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00289601 · ClinicalTrials.gov registry record · Phase 4
Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1,200
- Enrollment target
NCT00289601 is a Phase 4 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 1,200 participants.
The verdict
NCT00289601, a Phase 4 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1,200 participants
- Enrollment target
Study Summary
This study is a randomized, double-blind, multi-center study designed to compare differences in rates of myonecrosis (measured as an elevation of CK-MB ratio ≥ 2 times ULN) within 24 hours following low-medium risk percutaneous coronary intervention (PCI) in aspirin or clopidogrel non-responsive patients who are randomized to heparin with or without eptifibatide therapy during PCI. The primary objective of this study is to determine if the use of eptifibatide is associated with a significant difference in post-PCI myonecrosis (measured as an elevation of CK-MB ratio ≥ 2 times upper limit of normal \[ULN\]) within 24 hours of low-medium risk PCI in patients who are aspirin or non-responsive as determined by VerifyNow Aspirin and P2Y12 testing.
Interventions
- DRUG eptifibatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00289601
The ClinicalTrials.gov registry entry for NCT00289601 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eptifibatide is the first listed.
NCT00289601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00289601 about?
NCT00289601 is a clinical study titled "Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty". This study is a randomized, double-blind, multi-center study designed to compare differences in rates of myonecrosis (measured as an elevation of CK-MB ratio ≥ 2 times ULN) within 24 hours following low-medium risk percutaneous coronary intervention (PCI) in aspirin or clopidogrel non-responsive pat...
What is the current status of trial NCT00289601?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1,200 participants. The study started on 2006-03. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00289601?
The interventions under investigation include: eptifibatide (DRUG).
Who is sponsoring clinical trial NCT00289601?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.